Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Michael J. Keating et al.|New England Journal of Medicine|2019Cited by 502
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D. DiNardo, Marina Konopleva, Caitlin R. Rausch et al.|American Journal of Hematology|2017Cited by 437
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Marina Konopleva, Sa A. Wang et al.|Blood|2016Cited by 385
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesReuben Benjamin, Jackie Chappell, Charlotte Graham et al.|The Lancet|2020Cited by 358
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Joseph D. Khoury, Audrey L. Lamb et al.|Blood|2016Cited by 346